14,01 $
2,71 %heute
Nasdaq, 26. Februar, 15:49 Uhr
ISIN
US98943L1070
Symbol
ZNTL
Berichte
Sektor
Industrie

Zentalis Pharmaceuticals Inc Aktie News

Neutral
GlobeNewsWire
13 Tage alt
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, will participate in a webcast ...
Positiv
Seeking Alpha
19 Tage alt
Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health is strong, with a healthy cash reserve that will sustain operations until 2026. ZNTL is strategically expanding azenosertib's utility across wider indications and forming partnerships to reduce clin...
Neutral
GlobeNewsWire
25 Tage alt
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on February 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-q...
Neutral
GlobeNewsWire
etwa ein Monat alt
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D.
Neutral
Accesswire
etwa 2 Monate alt
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or ...
Neutral
Business Wire
etwa 2 Monate alt
BOTHELL, Wash. & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025,...
Neutral
Accesswire
etwa 2 Monate alt
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or ...
Neutral
GlobeNewsWire
etwa 2 Monate alt
NEW YORK and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on January 2, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qu...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen